GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+5.34%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$633M
AUM Growth
+$633M
(-1.1%)
Cap. Flow
-$27.5M
Cap. Flow
% of AUM
-4.35%
Top 10 Holdings %
Top 10 Hldgs %
62.56%
Holding
43
New
11
Increased
8
Reduced
7
Closed
10
Top Buys
| 1 |
Larimar Therapeutics
LRMR
|
$35.8M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$30.5M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$25.6M |
| 4 |
United Therapeutics
UTHR
|
$19.2M |
| 5 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$14.3M |
Top Sells
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$43.8M |
| 2 |
ZGNX
Zogenix, Inc.
ZGNX
|
$39.2M |
| 3 |
Puma Biotechnology
PBYI
|
$34M |
| 4 |
Neurocrine Biosciences
NBIX
|
$33.2M |
| 5 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
$28.7M |
Sector Composition
| 1 | Healthcare | 91.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
PTC Therapeutics
PTCT
$3.92B
| $52.9M | 7.33% | 1,568,500 +28,678 | +2% | +$967K |
|
2
Kura Oncology
KURA
$686M
| $47.8M | 6.63% | 2,627,110 +246,264 | +10% | +$4.48M |
|
3
Iovance Biotherapeutics
IOVA
$807M
| $44.6M | 6.18% | 3,485,745 +164,572 | +5% | +$2.11M |
|
4
BioCryst Pharmaceuticals
BCRX
$1.74B
| $42.9M | 5.94% | 7,478,275 | – | – |
|
|
ONCE
5
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $41.4M | 5.73% | 500,000 -50,000 | -9% | -$4.14M |
|
|
XLRN
6
DELISTED
Acceleron Pharma Inc.
XLRN
| $36.8M | 5.1% | 758,000 +295,755 | +64% | +$14.3M |
|
|
7
Larimar Therapeutics
LRMR
$310M
| $35.8M | 4.96% | +3,500,000 | New | +$35.8M |
|
|
GBT
8
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $34.8M | 4.83% | 770,400 +33,769 | +5% | +$1.53M |
|
|
9
Acadia Pharmaceuticals
ACAD
$4.38B
| $30.5M | 4.23% | +2,000,000 | New | +$30.5M |
|
10
Exelixis
EXEL
$10.1B
| $28.7M | 3.98% | 1,334,793 +434,893 | +48% | +$9.36M |
|
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $25.6M | 3.55% | +260,100 | New | +$25.6M |
|
|
FOMX
12
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $24M | 3.32% | 4,781,708 | – | – |
|
13
NovoCure
NVCR
$1.38B
| $22.3M | 3.1% | 713,998 -39,483 | -5% | -$1.24M |
|
|
FPRX
14
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $19.9M | 2.76% | 1,260,000 +391,900 | +45% | +$6.2M |
|
|
15
United Therapeutics
UTHR
$13.8B
| $19.2M | 2.66% | +169,639 | New | +$19.2M |
|
16
Voyager Therapeutics
VYGR
$186M
| $14.3M | 1.98% | +730,010 | New | +$14.3M |
|
|
ALXN
17
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $13.7M | 1.9% | +110,506 | New | +$13.7M |
|
18
Savara
SVRA
$567M
| $13.3M | 1.84% | 1,174,541 +312,362 | +36% | +$3.54M |
|
|
ARNA
19
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $13.2M | 1.82% | 302,000 -1,003,887 | -77% | -$43.8M |
|
20
Cytokinetics
CYTK
$4.23B
| $12M | 1.66% | +1,444,481 | New | +$12M |
|
21
Protagonist Therapeutics
PTGX
$3.67B
| $9.9M | 1.37% | +1,473,609 | New | +$9.9M |
|
22
Rigel Pharmaceuticals
RIGL
$697M
| $9.64M | 1.34% | 3,407,840 -5,171,614 | -60% | -$14.6M |
|
|
ACHN
23
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $8.46M | 1.17% | 2,988,716 -711,284 | -19% | -$2.01M |
|
|
CTIC
24
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $7.65M | 1.06% | 1,537,020 -150,000 | -9% | -$747K |
|
|
SRRA
25
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $6.75M | 0.94% | 2,280,921 -830,190 | -27% | -$2.46M |
|